Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel
Top Cited Papers
- 1 August 2021
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 300 (2), E323-E327
- https://doi.org/10.1148/radiol.2021210436
Abstract
Vaccination-associated adenopathy is a frequent imaging finding after administration of COVID-19 vaccines that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. To help the medical community address this concern in the absence of studies and evidence-based guidelines, this paper offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States. According to these recommendations, some routine imaging examinations, such as those for screening, should be scheduled before or at least 6 weeks after the final vaccination dose to allow for any reactive adenopathy to resolve. However, there should be no delay of other clinically indicated imaging (e.g., for acute symptoms, short-interval treatment monitoring, urgent treatment planning or complications) due to prior vaccination. The vaccine should be administered on the side contralateral to the primary or suspected cancer, and both doses should be administered in the same arm. Vaccination information (date(s) administered, injection site(s), laterality, and type of vaccine) should be included in every pre-imaging patient questionnaire, and this information should be made readily available to interpreting radiologists. Clear and effective communication between patients, radiologists, referring physician teams and the general public should be considered of the highest priority when managing adenopathy in the setting of COVID-19 vaccination. Summary COVID-19-vaccination–related adenopathy is a frequent imaging finding that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. This special report offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States.Funding Information
- National Institutes of Health/National Cancer Institute Cancer Center (P30 CA008748)
This publication has 13 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Covid-19: New coronavirus variant is identified in UKPublished by BMJ ,2020
- Effects of the COVID-19 Pandemic on Cancer-Related Patient EncountersJCO Clinical Cancer Informatics, 2020
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet Oncology, 2020
- The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling studyThe Lancet Oncology, 2020
- Non-invasive molecular imaging of immune cell dynamics for vaccine researchClinical and Experimental Vaccine Research, 2019
- Systemic Immune Response to Vaccination on FDG-PET/CTNuclear Medicine and Molecular Imaging, 2015
- FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1)European Radiology, 2010
- Clinical Responses to Undiluted and Diluted Smallpox VaccineThe New England Journal of Medicine, 2002
- Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanomaCancer, 2000